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INTRODUCTION
Reactivation of hepatitis-B virus (HBV) infection in patients
receiving cytotoxic chemotherapy for hematologic malignan-
cies is well documented (1-4). The severity of the hepatitis
ranges from anicteric hepatitis to severe, progressive hepatic
failure that may result in death (1, 2, 5-17). In an endemic
area for chronic hepatitis-B infection, reactivation of this virus
is a serious cause of morbidity and mortality in patients under-
going cytotoxic chemotherapy.
Possible mechanisms to explain reactivation include enhance-
ment of viral replication leading to an increase in the number
of infected hepatocytes. After withdrawal of the immunosup-
pressive agent and restoration of immunocompetence, acti-
vated T lymphocytes may attack the infected hepatocytes, lead-
ing to their rapid destruction (18-21).
In Japan, 53% of lymphoma patients with chronic HBV
infection developed severe hepatitis during chemotherapy, and
this was associated with a high mortality of 24% (16). Another
survey in Hong Kong has shown that the rate of HBV reac-
tivation was more likely to develop in patients with Non-
Hodgkin’ s Lymphoma (NHL) than in those with other malig-
nancies, probably reflecting the more immunosuppressive treat-
ment the lymphoma patients received (17).
Because these episodes of hepatitis are preceded by a substan-
tial increase in HBV replication during the immunosuppres-
sive phase, a rational approach to patient management would
include the use of specific nucleoside analogues that selectively
block HBV replication. Lamivudine is a reverse transcriptase
inhibitor of viral DNA polymerase with an excellent profile
of safety and tolerability, causing inhibition of viral replication
and approved as an antiviral treatment in hepatitis-B virus
infected patients (2, 22, 23).
Recently, prophylactic therapy of lamivudine was reported
to be effective for the treatment and prevention of hepatitis
due to exacerbation of HBV (24, 25). Despite the introduc-
tion and use of lamivudine, some HBsAg-positive patients
still developed hepatic failure and died (25, 26). This is prob-
ably related to the late institution of the nucleoside analogues
when hepatitis due to reactivation of HBV has already been
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The Prophylactic Use of Lamivudine Can Maintain Dose-Intensity of
Adriamycin in Hepatitis-B Surface Antigen (HBs Ag)-positive Patients
with Non-Hodgkin’ s Lymphoma Who Receive Cytotoxic Chemotherapy
We investigated the effectiveness of lamivudine to prevent hepatitis flare up due to
reactivation of hepatitis-B virus (HBV) in hepatitis-B surface antigen (HBsAg)-posi-
tive patients with Non-Hodgkin’ s lymphoma (NHL) during cytotoxic chemotherapy.
HBsAg-positive patients with NHL were identified from the lymphoma database of the
Asan Medical Center from January 1995 to August 2002, and their medical records
were reviewed. We found that 31 patients were received cytotoxic chemotherapy
among 41 NHL patients with HBsAg-positive during same period. We divided them
into 2 groups of HBsAg patients with NHL as follows: Group A who received cytotoxic
chemotherapy with lamivudine 100 mg daily; Group B without any prophylactic
antiviral therapy. There were no significant differences between Group A and B in
several clinical variables. Seventeen patients (85%) in group B and one patient (9%)
in Group A had hepatitis due to reactivation of HBV (p<0.001), with one hepatic fail-
ure related death in Group B and none in group A. The mean dose intensity of adri-
amycin actually delivered was 13.3 mg/m
2/week (80% Relative Dose intensity (RDI))
in Group A and 9.1 mg/m
2/week (55% RDI) in Groups B (p<0.001). Our data suggest
that the frequency of chemotherapy-related HBV reactivation may be significantly
decreased by lamivudine prophylaxis with maintenance of the dosage of adriamycin.
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py Protocols; Chemoprevention
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developed (25). Therefore, a better strategy might be to use
nucleoside analogues preemptively before the cytotoxic chemo-
therapy and hence to prevent the enhancement of HBV repli-
cation during the early immunosuppressive period (25, 27).
In this study, we analyzed the effectiveness of preemptive
use of lamivudine in preventing hepatitis due to exacerbation
of HBV in HBsAg-positive patients with NHL during cytotox-
ic chemotherapy.
PATIENTA AND METHODS
Patients
1,333 adult patients diagnosed as de novo NHL in the Asan
Medical Center from January 1995 to August 2002 were in-
cluded in the study. We identified 41 patients with serolog-
ical evidence of HBsAg-positive. After exclusion of 10 patients
who did not receive cytotoxic chemotherapy as follows: sepsis
due to unknown etiology in 1; pneumonia and multiorgan
dysfunction syndrome in 2; patient’ s own refusal in 2; double
primary malignancies in 3 (2 patients with underlying hep-
atocellular carcinoma; 1 patient with non-small cell lung can-
cer with multiple brain metastasis); and follow-up loss after
pathologic diagnosis in 2 patients. We reviewed the medical
records and collected the clinical data from 31 patients who
were selected from the database of the Asan Medical Center,
and who underwent chemotherapy among 41 patients.
We divided them into 2 groups of HBsAg-positive patients
with NHL as follows: Group A who received lamivudine 100
mg daily (n=11); Group B who received cytotoxic chemothera-
py without any prophylactic antiviral therapy (n=20).
Laboratory Studies
In accordance with our standard admission protocol, all pa-
tients with NHL were screened and tested in serum by com-
mercially available immunoassay kits for hepatitis-B serolo-
gy (Diasorin, A6K-3
� RIA-IRMA Immuno-RadioMetric
Assay): [HBsAg, anti-HBs, HBeAg, anti-HBe, antiHBc IgM
and IgG]; serum biochemistry [protein, albumin, bilirubin,
alkaline phosphatase (ALP), aspartate aminotransferase (AST),
alanine aminotransferase (ALT)]; HCV antibody; and HBV
DNA if needed before cytotoxic chemotherapy.
Definition of Hepatitis and Hepatic Failure
For the purpose of this study,  “hepatitis” was defined as three-
fold or greater increase in serum ALT level that exceeded the
reference range (>40 IU/L). Icteric hepatitis was defined as
serum bilirubin level that exceeded the reference range (<1.2
mg/dL) by twice in the absence of clinical or laboratory fea-
tures of acute infection with HAV, HCV, delta virus, or other
systemic infections, malignant hepatic infiltration (detected
by imaging studies), and alcoholism.  “Chronic hepatitis” was
defined as presence of persistent elevated liver enzyme and
past medical history of overt hepatitis continued for at least 6
months. “Liver cirrhosis” was diagnosed by means of laboratory
(hypoalbuminemia and thrombocytopenia less than 150,000
per microliter with or without jaundice) and radiological find-
ings by using of non-invasive abdominal ultrasonography,
which was not implicated in intra-abdominal involvement
of lymphoma. In our study, hepatic failure was defined as the
presence of hepatic encephalopathy and blood coagulopathy
(prolonged prothrombin time).
Statistical Analysis
The Fisher’ s exact test was used to compare the baseline
characteristics, hepatic events, and outcomes in patients
treated with lamivudine (Group A) to those without any antivi-
ral therapy (Group B), whereas continuous variables were com-
pared by using the Mann-Whitney U test.
Dose intensity (DI) of doxorubicin was evaluated accord-
ing to the method of Hryniuk and Bush (28). Expression of
the actual DI was calcaulated by dividing the actual total dose
of doxorubicin in standard CHOP regimen by the time (3
weeks). Calculation was carried out for the whole treatment
period and separately for the initial cycles to achieve the max-
imal response or to determine the progression of disease. Rel-
ative dose intensity (RDI) in patients was compared by using
independent sample t-test. The rates of survival of group A
and B was calculated by using Kaplan-Meier method, cen-
soring at last follow-up and death. 95% confidence intervals
for all estimates were also provided where appropriate p-val-
ues less than 0.05 were considered to be significant through-
out this study. Analysis of the data was performed by using
SPSS for Windows V. 10.0 (SPSS inc, Chicago, IL, U.S.A.)
statistical software program.
RESULTS
Comparison of Baseline Characteristics of Groups A
and B
We found that thirty one patients (19 men and 12 women),
aged 18-70 yr (median, 47 yr), who received cytotoxic chemo-
therapy were HBsAg-positive with NHL between January
1995 and August 2002 at Asan Medical Center. The patho-
logic subtypes were as follows: diffuse large B cell in 27 (87%)
patients, follicular lymphoma in 2 (7%) patients, peripheral
T cell lymphoma in 1 (3%) patient, and extranodal NK/T
cell lymphoma, nasal type in 1 (3%) patient. The first-line
chemotheraphy regimens included: CHOP (cyclophosphamide
750 mg/m2 iv day 1, adriamycin in 50 mg/m2 iv day 1, vin-
cristine 1.4 mg/m2 iv day 1, prednisolone 40 mg/m2po day 1-
5) in 29 (94%) patients; EDAP (etoposide 100 iv mg/m2iv dayLamivudine Prophylaxis in Chemotherapy of Non-Hodgkin’ s Lymphoma 851
1-4, dexamethasone 40 mg/m2 po day 1-5, cytosine arabinoside
1,000 mg/m2 continuous intravenous infusion, cisplatin 25
mg/m2iv days 1-4) in 1 (3%) patient; and proMACE-cytaBOM
(prednisolone 60 mg/m2 per po days 1-14, adramycin 25 mg/
m2 iv day 1, cyclophosphamide 650 mg/m2 iv day 1, etopo-
side 120 mg/m2 iv day 1, cytosine arabinoside 300 mg/m2 iv
day 8, methotrexate 120 mg/m2 iv day 8, leucovorin 15 mg
po day 9, bleomycin 5 units/m2, vincristine 1.4 mg/m2 iv day
8) in 1 (3%) patient. The number of course of cytotoxic ther-
apy ranged from 2-13 (median 5). As a rule, we did not mod-
ify the dose of steroid like other chemotherapeutic agents, irre-
spective of underlying liver function of patients who received
cytotoxic chemotherapy.
There were no differences between Group A and Group B
in sex, age, underlying liver disease, stage, IPI (International
Prognostic Index) score, B symptom, hepatic involvement
of NHL, HBV serology, HBV DNA, and precore mutant
(Table 1).
Hepatitis due to Exacerbation of HBV after Cytotoxic
Chemotherapy
Seventeen patients (85%) in Group B and one patient (9%)
in Group A had hepatitis due to reactivation of HBV, with
one hepatic failure related death in Group B and none in Group
A. Five patients in Group B started to receive lamivudine after
stabilization of first attack of hepatitis flare-up, and none of
them experienced hepatitis due to reactivation HBV from the
beginning of lamivudine treatment. After cytotoxic chemother-
apy, there were significantly more episodes of hepatitis due to
exacerbation of HBV in Group B than in Group A (p<0.001).
Comparison of hepatitis flare-up between patients
positive for HBeAg and those positive HBeAb (anti-
HBe)
There were no statistical differences between patients with
HBeAg and those with anti-HBe in sex, age, underlying liver
disease, stage, IPI score, B symptom, hepatic involvement of
NHL (Table 2).
*: Fisher’ s exact analysis, 
� : Pearson chi-square test.
Group A
(n=11)
Group B
(n=20)
p
Use of lamividine Yes No
Median age (yr) (range) 44 (29-68) 47.5 (18-70) 0.649
Sex 0.705
�
Male 6 (55%) 13 (65%)
Female 5 (45%) 7 (35%)
Immunophenotype 0.591*
B cell 10 (91%) 19 (95%)
T cell 1 (9%) 1 (5%)
Stage 1.000*
1/2 7 (64%) 12 (60%)
3/4 4 (36%) 8 (40%)
IPI score 1.000*
Low/low intermediate 7 (64%) 12 (60%)
High intermediate/high 4 (36%) 8 (40%)
B symptom 0.106*
Yes 3 (27%) 3 (15%)
No 8 (73%) 17 (85%)
Hepatic involvement of lymphoma 0.158*
Yes 3 (27%) 4 (20%)
No 8 (73%) 16 (80%)
Underlying liver disease 0.749*
Asymptomatic 3 (27%) 4 (20%)
Chronic hepatitis 6 (55%) 10 (50%)
Liver cirrhosis 2 (18%) 6 (30%)
Hbe Ag/Ab 0.056*
+/- 7 (64%) 5 (25%)
-/+ 4 (36%) 15 (75%)
HBV-DNA 0.452
�
+ 5 (45%) 6 (30%)
- 6 (55%) 14 (70%)
Precore mutant 0.383*
Yes 1 (9%) 5 (25%)
No 10 (91%) 15 (75%)
Table 1. Baseline characteristics of Group A and B
*: Fisher’ s exact analysis, 
� : Pearson chi-square test.
Anti-HBe HBeAg p-value
Age (yr) 1.000*
<60 15 (79%) 9 (75%)
≥60 4 (21%) 3 (25%)
Sex
Male 12 (63%) 7 (58%) 1.000
�
Female 7 (37%) 5 (42%)
B symptom 1.000*
Yes 6 (32%) 3 (25%)
No 13 (68%) 9 (75%)
Immunophenotype
B cell 18 (95%) 11 (92%) 1.000*
T cell 1 (5%) 1 (8%)
Stage
1/2 9 (47%) 6 (50%) 1.000
�
3/4 10 (53%) 6 (50%)
IPI score
Low/low intermediate 11 (58%) 8 (67%) 0.717*
High intermediate/high 8 (42%) 4 (33%)
Hepatitis/Hepatic failure 0.060*
Yes 14 (74%) 4 (33%)
No 5 (26%) 8 (67%)
Lamivudine prophylaxis 0.056*
Yes 4 (21%) 7 (58%)
No 15 (79%) 5 (42%)
Underlying liver disease 0.652*
Asymptomatic 4 (21%) 3 (25%)
Chronic hepatitis 9 (47%) 7 (58%)
Liver cirrhosis 6 (32%) 2 (17%)
Hepatic involvement 1.000*
Yes 4 (21%) 2 (17%)
No 15 (79%) 10 (83%)
Table 2. Baseline characteristics of patients with HBeAb (anti-
HBe) and those with HBeAg852 G.-W. Lee, M.-H. Ryu, J.-L. Lee, et al.
Among 19 patients with anti-HBe prior to chemotherapy,
flare-up hepatitis developed in 14 patients (74%) and four
patients (33%) experienced hepatitis due to HBV reactivation
in 12 patients with HBeAg before cytotoxic chemotherapy
(p=0.060). The proportions of patients receiving prophylac-
tic lamivudine therapy were 20% (4 of 19) in the patients
with anti-HBe, as compared with 58% (7 of 12) in those with
HBeAg (p=0.056). Six of fourteen patients with anti-HBe
were identified as precore mutant HBV.
Comparison of Dose Intensity of Adriamycin and 
Survival of Group A and B
Dose reduction of adriamycin was required in patients who
developed hepatitis flare-up and abnormal liver function at
initial presentation among 29 patients who were treated by
using standard CHOP regimen as the first line chemotherapy
(Table 3); as a consequence, the mean DI of adriamycin actu-
ally delivered was 13.3 mg/m2/week in Group A and 9.1 mg/
m2/week in Group B, which represented 80% RDI in Group
A and 55% RDI in Group B (p<0.001) (Fig. 1). Survival rate
of Group A was higher than that of Group B. However, the
statistical difference of survival rates between Group A and
Group B was not significant (p=0.691) (Fig. 2).
DISCUSSION
With the more widespread use of chemotherapy, the pos-
sibility of HBV reactivation is becoming an increasing prob-
lem that may adversely affect the final outcome of treatment.
Cytotoxic chemotherapy for malignancy, particularly among
HBsAg-positive patients, may induce acute exacerbation of
hepatitis-B and also fulminant hepatic failure, especially when
chemotherapy is withdrawn (1-17). However, it is not possible
to predict the occurrence and the clinical severity of HBV
reactivation in a single patient. HBV reactivation is a partic-
ularly important clinical issue in areas such as Korea, where
HBV infection is endemic. The HBV carriers among the gen-
eral population is around at 5.1% in Korea (29).
Patients with hematological malignancies may be at increased
risk of HBV reactivations, as corticosteroid are more often
components of their chemotherapy regimen compared with
patients with other solid malignancies who received chemother-
apy not containing corticosteroid. Indeed, the presence of
corticosteroids among the protocol drugs is considered the
most important predisposing factor for HBV reactivation fol-
lowing chemotherapy (16, 30). In a retrospective study of 105
HBV carriers with malignant lymphoma, 22 (21%) developed
hepatic failure and six (27%) of them died from hepatic fail-
ure following cessation of cytotoxic treatment (1).
DI is a very important determinant of the response of NHL.
DeVita et al. (31) reported a close association between DI and
survival time. Kwak et al. (32) reported a significant correla-
tion between the relative DI for cyclophosphamide or adria-
mycin and survival time in patients with diffuse large cell
lymphoma. In fact, dose of chemotherapy in cases of HBsAg-
positive patients may sometimes be affected and modified by
underlying liver function, regardless of hepatic involvemet N: Number of evaluable patients; RDI: Relative dose-intensity.
Relative dose intensity (mg/m
2/week)
Cycle number With Lamivudine
(RDI)
Without 
Lamivudine (RDI)
p-value
1 (n=29) 13.28±0.60 (80%) 10.87±0.62 (65%) 0.296
2 (n=25) 13.12±0.38 (79%) 8.14±1.10 (49%) <0.001
3 (n=23) 12.55±1.22 (75%) 9.26±1.50 (56%) 0.524
4 (n=15) 13.80±0.59 (83%) 9.81±1.30 (59%) 0.112
5 (n=11) 13.79±0.69 (83%) 7.49±2.74 (45%) 0.081
Table 3. Relative dose intensities (mg/m
2/week) of adriamycin
given at each chemotherapy cycles
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Fig. 1. Comparison of dose intensity of adriamycin between Group
with lamivudine and Group without lamivudine.
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Fig. 2. Overall survival of Group A and B (p=0.691), Black solid
line: survival curve of lamivudine group. Dotted line: survival curve
without lamivudine prophylactic group.
With Lamivudine
p=0.691
Without Lamivudineof lymphoma. The hepatotoxicity of chemotherapy needs spe-
cial caution. Also, as 24 of 31 HBsAg-positive patients (77%)
in our study had impaired liver function test before therapy,
the use of cytotoxic agents such as adriamycin, which depends
on hepatic metabolism, demands special attention. Hepati-
tis-B flare-up after chemotherapy and abnormal liver func-
tion at initial presentation may also cause reduced dose-inten-
sity of adriamycin as shown in Fig. 1. Survival rate of Group
A which maintained relatively higher dose intensity of adri-
amycin by help of lamivudine was better than that of Group
B although the result was statistically not significant (p=0.691).
Lamivudine has been used more extensively, and has proven
effective both as a treatment and as a secondary prevention of
chemotherapy-related HBV reactivation (25, 33).
Our results showed that higher proportion of hepatitis flare-
up developed in patients with anti-HBe (74%, 14 of 19) com-
pared with those with HBeAg (33%, 4 of 12). This results
suggested that the lower proportion of lamivudine prophy-
laxis involved the increased risk of hepatitis flare-up in patients
with anti-HBe (20%, 4 of 19), as compared with patients who
were HBeAg positve (58%, 7 of 12) and the lower proportion
of hepatitis flare-up induced by active lamivudine prophylax-
is in patients with HBeAg. In six cases with anti-HBe who
experienced hepatitis due to HBV reactivation, the virus was
thought to have precore mutation. This results also suggest-
ed precore mutant plays an important role in HBV reactiva-
tion in NHL who received cytotoxic chemotherapy (26, 34).
Furthermore, the development of chronic hepatitis may
preclude the subsequent completion of the treatment sched-
ule for the hematological malignancies. The toxicity profiles
of lamivudine is particularly favorable because it does not over-
lap with those of other antiviral agents, making this agent
particularly suitable for a simultaneous use with chemother-
apy. Our results suggest that lamivudine may be used safely
along with supporting DI of adriamycin.
In conclusion, the present study suggests that lamivudine
can be given safely in association with chemotherapy with-
out causing significant adverse effects, a reduction of the dosage
or the efficacy of cytotoxic drugs. The frequency and the sever-
ity of chemotherapy-related HBV reactivation may be sig-
nificantly decreased by lamivudine prophylaxis.
Because our results have limitation that there is no serial
follow-up of several serologic markers during and after cytotox-
ic chemotherapy as a single institutional retrospective non-
randomized study, well-designed, prospective multicenter
trials are needed with serial quantification of HBV-DNA,
liver function evaluation, several serologic markers and seri-
al documentation of liver histology.
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